Asn194Lys mutation in RVG29 peptide increases GFP transgene delivery by endocytosis to neuroblastoma and astrocyte cells
- 23 June 2017
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 69 (10) , 1352-1363
Abstract
Objectives: A cell-penetrating peptide-based delivery system could target specific types of cells for therapeutic genes delivery. To increase the gene delivery efficiency into neuronal phenotype cells, we introduced an Asn194Lys mutation to RVG29 peptide derived from rabies virus glycoprotein and added a nuclear localization signal to enhance its nuclear import. Methods: Mutant RVG or wild-type RVG peptide, a karyophilic peptide (KP) and a plasmid encoding green fluorescent protein (pGL) were bound by electrostatic charges to form four different kinds of RVG complexes. Immunofluorescence was used to assess the gene transfection efficiency into astrocytes, oligodendrocyte precursor cells (OPCs), SH-SY5Y, HeLa and NIH/3T3 cells. The cellular uptake mechanism of RVG29 complexes was examined using endocytosis inhibitors. Key findings: The mRVG29 peptide has the ability to enhance the nuclear import of plasmids. The Asn194Lys mutation in RVG29 peptide of the pGL-mRVG29 complex and the addition of KP to the pGL-RVG29-KP complex increased the capacity to deliver DNA by endocytosis in astrocytes and SH-SY5Y cells. Conclusions: The complexes pGL-mRVG29 and pGL-RVG29-KP have specificity for transfecting astrocytes and SH-SY5Y cells. The karyophilic capacity of this new mRVG peptide render it promising candidate to act as gene delivery vector into the brain cells.Keywords
Funding Information
- PAICYT (SA196-15)
- UANL
- PRODEP
This publication has 34 references indexed in Scilit:
- Blood brain barrier: An overview on strategies in drug delivery, realisticin vitromodeling andin vivolive trackingTissue Barriers, 2015
- Challenges and New Strategies for Therapeutic Peptide Delivery to the CNSTherapeutic Delivery, 2015
- Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulationFluids and Barriers of the CNS, 2012
- Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeuticsBritish Journal of Pharmacology, 2009
- Glial cells as intrinsic components of non-cell-autonomous neurodegenerative diseaseNature Neuroscience, 2007
- Transvascular delivery of small interfering RNA to the central nervous systemNature, 2007
- Cell-penetrating peptides: tools for intracellular delivery of therapeuticsCellular and Molecular Life Sciences, 2005
- Alternative therapy of Alzheimer’s disease via supplementation with choline acetyltransferaseNeuroscience Letters, 2004
- Gene therapy of the brainNeurology, 2004
- Is the Acetylcholine Receptor a Rabies Virus Receptor?Science, 1982